Skip to main content
NCBI home page
Protein & Cell logoLink to Protein & Cell
. 2011 Dec 17;2(11):899–905. doi: 10.1007/s13238-011-1096-0

Parkinson disease drug screening based on the interaction between D2 dopamine receptor and beta-arrestin 2 detected by capillary zone electrophoresis

Zheng Zhou 1, Jun-Ming Liao 1, Peng Zhang 1, Jun-Bao Fan 1, Jie Chen 1, Yi Liang 1,✉
PMCID: PMC4875183  PMID: 22180089

Abstract

Parkinson’s disease is the second most common neurodegenerative disease in the world. Beta-arrestin-2 has been reported to be an important protein involved in D2 dopamine receptor desensitization, which is essential to Parkinson’s disease. Moreover, the potential value of pharmacological inactivation of G protein-coupled receptor kinase or arrestin in the treatment of patients with Parkinson’s disease has recently been shown. We studied the interaction between D2 dopamine receptor and beta-arrestin-2 and the pharmacological regulation of chemical compounds on such interaction using capillary zone electrophoresis. The results from screening more than 40 compounds revealed three compounds that remarkably inhibit the beta-arrestin-2/D2 dopamine receptor interaction among them. These compounds are promising therapies for Parkinson’s disease, and the method used in this study has great potential for application in large-scale drug screening and evaluation.

Keywords: drug screening, D2 dopamine receptor, beta-arrestin-2, capillary zone electrophoresis, protein-protein interaction, Parkinson’s disease

References

  1. Andersen P.H., Gingrich J.A., Bates M.D., Dearry A., Falardeau P., Senogles S.E., Caron M.G. Dopamine receptor subtypes: beyond the D1/D2 classification. Trends Pharmacol Sci. 1990;11:231–236. doi: 10.1016/0165-6147(90)90249-8. [DOI] [PubMed] [Google Scholar]
  2. Calabresi P., Mercuri N.B., Di Filippo M. Synaptic plasticity, dopamine and Parkinson’s disease: one step ahead. Brain. 2009;132:285–287. doi: 10.1093/brain/awn340. [DOI] [PubMed] [Google Scholar]
  3. Dagher A., Robbins T.W. Personality, addiction, dopamine: insights from Parkinson’s disease. Neuron. 2009;61:502–510. doi: 10.1016/j.neuron.2009.01.031. [DOI] [PubMed] [Google Scholar]
  4. DeWire S.M., Ahn S., Lefkowitz R.J., Shenoy S.K. β-arrestins and cell signaling. Annu Rev Physiol. 2007;69:483–510. doi: 10.1146/annurev.physiol.69.022405.154749. [DOI] [PubMed] [Google Scholar]
  5. Ding L., Zhang X.X., Wei P., Fan K., Lai L. The interaction between severe acute respiratory syndrome coronavirus 3C-like proteinase and a dimeric inhibitor by capillary electrophoresis. Anal Biochem. 2005;343:159–165. doi: 10.1016/j.ab.2005.04.027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dodd M.L., Klos K.J., Bower J.H., Geda Y.E., Josephs K.A., Ahlskog J.E. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol. 2005;62:1377–1381. doi: 10.1001/archneur.62.9.noc50009. [DOI] [PubMed] [Google Scholar]
  7. Dromey J.R., Pfleger K.D. G protein coupled receptors as drug targets: the role of β-arrestins. Endocr Metab Immune Disord Drug Targets. 2008;8:51–61. doi: 10.2174/187153008783928352. [DOI] [PubMed] [Google Scholar]
  8. Emilien G., Maloteaux J.M., Geurts M., Hoogenberg K., Cragg S. Dopamine receptors-physiological understanding to therapeutic intervention potential. Pharmacol Ther. 1999;84:133–156. doi: 10.1016/S0163-7258(99)00029-7. [DOI] [PubMed] [Google Scholar]
  9. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C.W., Tanner C., Marek K., the Parkinson Study Group Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498–2508. doi: 10.1056/NEJMoa033447. [DOI] [PubMed] [Google Scholar]
  10. Gainetdinov R.R., Premont R.T., Bohn L.M., Lefkowitz R.J., Caron M.G. Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci. 2004;27:107–144. doi: 10.1146/annurev.neuro.27.070203.144206. [DOI] [PubMed] [Google Scholar]
  11. García-Campaña A.M., Taverna M., Fabre H. LIF detection of peptides and proteins in CE. Electrophoresis. 2007;28:208–232. doi: 10.1002/elps.200500790. [DOI] [PubMed] [Google Scholar]
  12. Goldman-Rakic P.S., Castner S.A., Svensson T.H., Siever L.J., Williams G.V. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 2004;174:3–16. doi: 10.1007/s00213-004-1793-y. [DOI] [PubMed] [Google Scholar]
  13. Holzgrabe U., Brinz D., Kopec S., Weber C., Bitar Y. Why not using capillary electrophoresis in drug analysis? Electrophoresis. 2006;27:2283–2292. doi: 10.1002/elps.200600016. [DOI] [PubMed] [Google Scholar]
  14. Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368–376. doi: 10.1136/jnnp.2007.131045. [DOI] [PubMed] [Google Scholar]
  15. Kelly E., Bailey C.P., Henderson G. Agonist-selective mechanisms of GPCR desensitization. Br J Pharmacol. 2008;153:S379–S388. doi: 10.1038/sj.bjp.0707604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kobilka B.K., Deupi X. Conformational complexity of Gproteincoupled receptors. Trends Pharmacol Sci. 2007;28:397–406. doi: 10.1016/j.tips.2007.06.003. [DOI] [PubMed] [Google Scholar]
  17. Kostal V., Katzenmeyer J., Arriaga E.A. Capillary electrophoresis in bioanalysis. Anal Chem. 2008;80:4533–4550. doi: 10.1021/ac8007384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lefkowitz R.J., Shenoy S.K. Transduction of receptor signals by β-arrestins. Science. 2005;308:512–517. doi: 10.1126/science.1109237. [DOI] [PubMed] [Google Scholar]
  19. Levoye A., Jockers R. Alternative drug discovery approaches for orphan GPCRs. Drug Discov Today. 2008;13:52–58. doi: 10.1016/j.drudis.2007.09.011. [DOI] [PubMed] [Google Scholar]
  20. Ma L., Pei G. b-arrestin signaling and regulation of transcription. J Cell Sci. 2007;120:213–218. doi: 10.1242/jcs.03338. [DOI] [PubMed] [Google Scholar]
  21. Macey T.A., Gurevich V.V., Neve K.A. Preferential Interaction between the dopamine D2 receptor and Arrestin2 in neostriatal neurons. Mol Pharmacol. 2004;66:1635–1642. doi: 10.1124/mol.104.001495. [DOI] [PubMed] [Google Scholar]
  22. Mehler-Wex C., Riederer P., Gerlach M. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson’s disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res. 2006;10:167–179. doi: 10.1007/BF03033354. [DOI] [PubMed] [Google Scholar]
  23. Neve K.A., Seamans J.K., Trantham-Davidson H. Dopamine receptor signaling. J Recept Signal Transduct Res. 2004;24:165–205. doi: 10.1081/RRS-200029981. [DOI] [PubMed] [Google Scholar]
  24. Oakley R.H., Laporte S.A., Holt J.A., Caron M.G., Barak L.S. Differential affinities of visual arrestin, β arrestin1, and β arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem. 2000;275:17201–17210. doi: 10.1074/jbc.M910348199. [DOI] [PubMed] [Google Scholar]
  25. Obeso J.A., Marin C., Rodriguez-Oroz C., Blesa J., Benitez-Temiño B., Mena-Segovia J., Rodríguez M., Olanow C.W. The basal ganglia in Parkinson’s disease: current concepts and unexplained observations. Ann Neurol. 2008;64:S30–S46. doi: 10.1002/ana.21481. [DOI] [PubMed] [Google Scholar]
  26. Olanow C.W., Obeso J.A., Stocchi F. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Nat Clin Pract Neurol. 2006;2:382–392. doi: 10.1038/ncpneuro0222. [DOI] [PubMed] [Google Scholar]
  27. Premont R.T., Gainetdinov R.R. Physiological roles of G protein-coupled receptor kinases and arrestins. Annu Rev Physiol. 2007;69:511–534. doi: 10.1146/annurev.physiol.69.022405.154731. [DOI] [PubMed] [Google Scholar]
  28. Premont R.T., Inglese J., Lefkowitz R.J. Protein kinases that phosphorylate activated G protein-coupled receptors. FASEB J. 1995;9:175–182. doi: 10.1096/fasebj.9.2.7781920. [DOI] [PubMed] [Google Scholar]
  29. Reiter E., Lefkowitz R.J. GRKs and β-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab. 2006;17:159–165. doi: 10.1016/j.tem.2006.03.008. [DOI] [PubMed] [Google Scholar]
  30. Rosenbaum D.M., Rasmussen S.G., Kobilka B.K. The structure and function of G-protein-coupled receptors. Nature. 2009;459:356–363. doi: 10.1038/nature08144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Savitt J.M., Dawson V.L., Dawson T.M. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest. 2006;116:1744–1754. doi: 10.1172/JCI29178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Skinbjerg M., Ariano M.A., Thorsell A., Heilig M., Halldin C., Innis R.B., Sibley D.R. Arrestin3 mediates D(2) dopamine receptor internalization. Synapse. 2009;63:621–624. doi: 10.1002/syn.20636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Whalen E.J., Rajagopal S., Lefkowitz R.J. Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol Med. 2011;17:126–139. doi: 10.1016/j.molmed.2010.11.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Wilson C.J., Copeland R.A. Spectroscopic characterization of arrestin interactions with competitive ligands: study of heparin and phytic acid binding. J Protein Chem. 1997;16:755–763. doi: 10.1023/A:1026311832660. [DOI] [PubMed] [Google Scholar]
  35. Xiao K., Shenoy S.K., Nobles K., Lefkowitz R.J. Activation-dependent conformational changes in β-arrestin 2. J Biol Chem. 2004;279:55744–55753. doi: 10.1074/jbc.M409785200. [DOI] [PubMed] [Google Scholar]
  36. Yang P., Whelan R.J., Mao Y., Lee A.W., Carter-Su C., Kennedy R.T. Multiplexed detection of protein-peptide interaction and inhibition using capillary electrophoresis. Anal Chem. 2007;79:1690–1695. doi: 10.1021/ac061936e. [DOI] [PubMed] [Google Scholar]

Articles from Protein & Cell are provided here courtesy of Oxford University Press

RESOURCES